BEAM

SEC source: 0000950170-25-049765 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,305

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-049763 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,650

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-049759 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,016,159

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-024149 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,527

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

SEC source: 0000950170-25-023166 · ownership.xml · derivative · entry 5

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,410

Underlying: Common Stock · 508 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option was fully vested.

SEC source: 0000950170-25-023166 · ownership.xml · derivative · entry 4

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,492 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option was fully vested.

SEC source: 0000950170-25-023166 · ownership.xml · nonDerivative · entry 3

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,968

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2024.

SEC source: 0000950170-25-023166 · ownership.xml · nonDerivative · entry 2

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2024.

SEC source: 0000950170-25-023166 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2024.

SEC source: 0000950170-25-012303 · ownership.xml · derivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-012307 · ownership.xml · derivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-012306 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2035-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-25-012305 · ownership.xml · derivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-25-012304 · ownership.xml · derivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2035-01-31

F3 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-012304 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 908,659

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

SEC source: 0000950170-25-012304 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 908,859

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-049297 · ownership.xml · derivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,336

Underlying: Common Stock · 30,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc.

F2 · security: (Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F4 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000950170-25-049297 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 968,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc.

F2 · security: (Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F4 · balance_after: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000950170-25-002355 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,814

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Peerson in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on December 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.21 to $25.02, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-002358 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,968

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.21 to $25.02, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-000624 · ownership.xml · derivative · entry 2

Emany Sravan Kumar · CIK 0001897662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2034-12-31

F2 · derivative.exercise_date: This stock option vests as to 25% on the first anniversary of the vesting commencement date, December 31, 2024, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000950170-25-000624 · ownership.xml · nonDerivative · entry 1

Emany Sravan Kumar · CIK 0001897662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in four substantially equal installments on each of the first four anniversaries of December 31, 2024, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-138447 · ownership.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,505

Underlying: Common Stock · 53,500 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0000950170-24-138447 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-133080 · ownership.xml · derivative · entry 1

Guindo Chirfi · CIK 0001722753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,086

Underlying: Common Stock · 39,086 shares

Expires 2034-12-02

F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date.

SEC source: 0000950170-24-124085 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,150

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.98, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 1,457 shares

Expires 2029-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F4 · derivative.exercise_date: This stock option vested as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option was fully vested.

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 12,979 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

SEC source: 0000950170-24-115031 · ownership.xml · derivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Comon Stock · 27,318 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,260

F2 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 211,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

SEC source: 0000950170-24-115031 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 196,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

SEC source: 0000950170-24-111737 · ownership.xml · nonDerivative · entry 2

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,931

F2 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs granted to the Reporting Person under the Plan on September 30, 2021. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.45 to $23.48, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-111739 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,209

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on September 30, 2021. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.46 to $23.48, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-111737 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,220

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-111732 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 938,659

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.26 to $25.24, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 316 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.

SEC source: 0000950170-24-102823 · ownership.xml · derivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-08-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0000950170-24-081492 · ownership.xml · nonDerivative · entry 2

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,805

F3 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0000950170-24-081492 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,553

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · balance_after: This reflects a correction to the previously reported amount of securities beneficially owned. Prior to the reported transaction, the Reporting Person beneficially owned 70,055 shares of common stock, not 70,060 shares.

SEC source: 0000950170-24-079065 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 998,343

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.17 to $24.93, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-070790 · ownership.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-070793 · ownership.xml · derivative · entry 1

Shaw Christi · CIK 0001702473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-070788 · ownership.xml · derivative · entry 1

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-070783 · ownership.xml · derivative · entry 1

COOPER GRAHAM K · CIK 0001396943 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-070768 · ownership.xml · derivative · entry 1

Walsh Kathleen E · CIK 0001667866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-070766 · ownership.xml · derivative · entry 1

Fishman Mark · CIK 0001786003 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,114

Underlying: Common Stock · 23,114 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-24-049854 · ownership.xml · derivative · entry 2

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-04-26

F2 · derivative.exercise_date: This stock option vests in equal monthly installments each month following July 31, 2023 for the subsequent thirty-six months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-049854 · ownership.xml · nonDerivative · entry 1

Burrell Terry-Ann · CIK 0001786484 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,637

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in three substantially equal annual installments on each of the first three anniversaries of September 30, 2023, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-24-041432 · ownership.xml · derivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,965

Underlying: Common Stock · 53,965 shares

Expires 2029-02-13

F4 · derivative.exercise_date: On February 13, 2019, the Reporting Person was granted an option to purchase 53,965 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 53,965 shares.